Market revenue in 2023 | USD 831.1 million |
Market revenue in 2030 | USD 1,884.5 million |
Growth rate | 12.4% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 65.59% in 2023. Horizon Databook has segmented the Germany circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
The branded generic market in Germany is expected to witness positive growth over the forecast period due to government funding and investments to support generic drug manufacturing. According to a study published in 2020, the country depends on 63% of APIs imported from Asian countries and 33% from European countries for manufacturing of generic products.
In Germany, there is high penetration of generics and fierce competition among the players. Germany is among the mature players in the EU with penetration of generics at about 35% by value and around 75% by volume. From a reimbursement and a regulatory perspective, it is a tender-driven market, where quality and price are considered crucial criteria.
The increase in generics players in the country contributes to fierce competition and pricing pressures. In addition, physicians are not required to prescribe according to INN and might choose to avoid substitutes by prescribing specific brands, which is expected to drive the market growth in Germany.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Germany circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account